About 1,000 Women in England Gain NHS Access to Enhertu for Advanced Breast Cancer

About 1,000 women a year in England with HER2-low advanced breast cancer can receive Enhertu on the NHS after NICE recommended routine use on 17 September 2026. The decision follows a price deal between ministers, NHS England, AstraZeneca and Daiichi Sankyo. Wales and Northern Ireland are likely to follow; Scotland has offered it since December 2023.